Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolerance and Efficacy of Rituximab in Sjogren's Disease.

Next Previous
Trial Profile

Tolerance and Efficacy of Rituximab in Sjogren's Disease.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 04 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary)
  • Indications Sjogren's syndrome
  • Focus Therapeutic Use
  • Acronyms TEARS

Most Recent Events

  • 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
  • 30 Oct 2013 Results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
  • 30 Oct 2013 Post-hoc analysis for the impact of various endpoints on the sample size presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top